Anti-TRIF (TICAM1) antibody [EPR24995-152],Abcam,AB302562

Target data Involved in innate immunity against invading pathogens. Adapter used by TLR3, TLR4 (through TICAM2) and TLR5 to mediate NF-kappa-B and interferon-regulatory factor (IRF) activation, and to induce apoptosis (PubMed : 12471095, PubMed : 12539043, PubMed : 14739303, PubMed : 28747347). Ligand binding to these receptors results in TRIF recruitment through its TIR domain (PubMed : 12471095, PubMed : 12539043, PubMed : 14739303). Distinct protein-interaction motifs allow recruitment of the effector proteins TBK1, TRAF6 and RIPK1, which in turn, lead to the activation of transcription factors IRF3 and IRF7, NF-kappa-B and FADD respectively (PubMed : 12471095, PubMed : 12539043, PubMed : 14739303). Phosphorylation by TBK1 on the pLxIS motif leads to recruitment and subsequent activation of the transcription factor IRF3 to induce expression of type I interferon and exert a potent immunity against invading pathogens (PubMed : 25636800). Component of a multi-helicase-TICAM1 complex that acts as a cytoplasmic sensor of viral double-stranded RNA (dsRNA) and plays a role in the activation of a cascade of antiviral responses including the induction of pro-inflammatory cytokines (By similarity). See full target information TICAM1